

Prescient Therapeutics Granted Key U.S. Patents for Novel Cancer Compound PTX-200

- ***Bolsters IP portfolio for PTX-200, an AKT inhibitor, now in Phase 1b/2 trial***
- ***Advancing development of potential new standard of care for chemotherapy-resistant ovarian cancer***

Melbourne, Australia, 23rd February 2015: Prescient Therapeutics (ASX: PTX), a clinical stage oncology company, announced today that the U.S. Patent and Trademark Office has granted two additional patents that underpin the development and commercialisation of its drug candidate PTX-200. U.S. patent 8,906,869, provides broad protection for the company's novel method of treating chemotherapy resistant ovarian cancer with the AKT inhibitor compound PTX-200, formerly known as TCN-P or triciribine phosphate monohydrate. The second U.S. patent 8,901,086, provides broad coverage for treating various cancer types including breast cancer by administering PTX-200 in combination with trastuzumab.

Dr. Robert Crombie, Managing Director of Prescient Therapeutics, said, "These U.S. patents further enhance our intellectual property portfolio. They confirm our monopoly rights on this novel and highly encouraging compound which we believe has significant potential to improve the clinical outcome for women with chemotherapy-resistant ovarian cancer."

"Prescient's drug candidate PTX-200 is being trialed in patients who have become resistant to platinum-based drugs as it inhibits the AKT tumor survival pathway associated with platinum drug resistance PTX-200, in combination with standard of care drug carboplatin, is currently in Phase 1b/2 trial as a new therapy for ovarian cancer, the fifth leading cause of cancer death in women in the United States. Currently approximately half of the patients diagnosed with ovarian cancer will die from metastatic disease as they become resistant to the platinum-based drugs that constitute front line therapy. Prescient's drug candidate PTX-200 is aiming to minimise this resistance."

About Prescient Therapeutics

Prescient Therapeutics is a clinical stage oncology company developing two novel drug candidates for the treatment of cancer. The company holds an exclusive worldwide license to the novel anti-cancer compound PTX-100 (formerly known as GGTI-2418) for the treatment of multiple myeloma, breast and pancreatic cancer. The company plans to initiate Phase 1b/2 clinical trial of PTX-100 in multiple myeloma in H1 2015.

Prescient is also developing PTX-200, a novel anti-cancer drug (formerly known as TCN-P) that inhibits the drug target AKT. PTX-200 is being progressed in two active Phase 1b/2 clinical trials in breast and ovarian cancers. These trials are funded by U.S. government authorities including grants from the Department of Defence and National Cancer Institute. The company plans to commence a Phase 1b/2 trial in patients with acute leukaemias that have become refractory to cytarabine, the current front line therapy for Acute Myeloid Leukaemia and Acute Lymphocytic Leukaemia.

In addition, the company has licensed its Co-X-Gene™ technology to the French biotechnology company Transgene for use in two of Transgene's immunotherapeutic products.



Contact:

Mr Rudi Michelson

Monsoon Communications
Ph: +61 (0) 3 9620 3333

Dr Robert Crombie

Managing Director
Ph: +61 (0) 439 361 331

Mr Paul Hopper

Executive Director
US +1 858 334 5820

Ms. Stephanie Carrington

ICR
Ph: 646-277-1282

